Subject: Applied Immune Sciences Filing
Date: Published: 4/7/93 (22 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    Applied Immune Sciences Filing

    SANTA CLARA, Calif.  -- Applied Immune Sciences Inc. said it filed
 an application with the Food and Drug Administration for clearance
 to market a device that isolates and removes certain potentially
 harmful cells from the bone marrow.
    The company, which is developing immune system therapies for
 cancer and AIDS, said its AIS CELLector device removes certain blood
 cells called T-cells from donor bone marrow before infusing it into
 a cancer patient.
    In clinical trials, the company said such treatment has shown the
 potential to prevent so-called graft vs. host disease, in which the
 donor's marrow attacks the host's tissue.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]